deltatrials
Not Yet Recruiting PHASE2 Interventional 3-arm NCT03760289

DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer (DYNAMIC)

DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer: a Multi-center Phase II Trial

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Conditions Biliary Tract Cancer Esophagogastric Cancer GastroEsophageal Cancer Hepatobiliary Neoplasm
Interventions Atezolizumab DKN-01 Paclitaxel
Updated 1 time since 2018 Last updated: Nov 29, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03760289, this PHASE2 trial focuses on Biliary Tract Cancer and Esophagogastric Cancer and remains actively recruiting participants. Sponsored by European Organisation for Research and Treatment of Cancer - EORTC, it has been updated 1 time since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Dec 2018 – present · 91 months · monthly snapshotNot Yet Recruiting

Change History

1 version recorded
Not Yet Recruiting — PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • European Organisation for Research and Treatment of Cancer - EORTC
  • Hoffmann-La Roche
  • Leap Therapeutics, Inc.
Data source: European Organisation for Research and Treatment of Cancer - EORTC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.